MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03291067 |
Recruitment Status :
Completed
First Posted : September 25, 2017
Results First Posted : January 4, 2022
Last Update Posted : January 4, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Menopause Hot Flashes | Drug: MT-8554 1mg Drug: MT-8554 5mg Drug: MT-8554 10mg Drug: Placebo | Phase 2 |
This is a Phase II randomized, double-blind, placebo-controlled study for dose selection in postmenopausal women with moderate to severe VMS, defined as follows:
- Moderate: sensation of heat with sweating, able to continue activity
- Severe: sensation of heat with sweating, causing cessation of activity This study is comprised of a screening period, a run-in period and a 12-week double-blind treatment period.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 375 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women |
Actual Study Start Date : | October 9, 2017 |
Actual Primary Completion Date : | October 19, 2018 |
Actual Study Completion Date : | November 9, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: MT-8554 1mg |
Drug: MT-8554 1mg
MT-8554 1mg QD, oral, 12 weeks |
Experimental: MT-8554 5mg |
Drug: MT-8554 5mg
MT-8554 5mg QD, oral, 12 weeks |
Experimental: MT-8554 10mg |
Drug: MT-8554 10mg
MT-8554 10mg QD, oral, 12 weeks |
Placebo Comparator: Placebo |
Drug: Placebo
Placebo QD, oral, 12 weeks |
- Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 [ Time Frame: Baseline, Weeks 4 and 12 ]The average daily frequency of moderate to severe VMS at a time point (Baseline, Weeks 4 and 12) was the average of the frequency of moderate to severe VMS of available diary days in a 7-day window. Changes in the average daily frequency of moderate to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.
- Change From Baseline in the Average Daily Severity Score of Mild to Severe VMS at Weeks 4 and 12 [ Time Frame: Baseline, Weeks 4 and 12 ]The daily severity score of VMS was defined as (2xFmo + 3xFse)/(Fmo + Fse) for baseline, and (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) for Weeks 4 and 12, where Fmi, Fmo, and Fse were the daily frequencies of mild, moderate, and severe VMS, respectively. The average daily severity score of mild to severe VMS at a time point (Baseline, Week 4 and Week 12) was the average of the daily severity of available diary days in the corresponding 7-day window. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity). Change in the average daily severity score of mild to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.
- Percentage of Responders at Weeks 4 and 12 [ Time Frame: Week 4 and Week 12 ]Subjects with cutoff number or greater reduction in the average daily frequency of moderate and severe VMS compared to baseline. The cutoff number was calculated using anchor-based method. The cutoff number was defined as numerical value to maximize the sensitivity and the specificity, using Patient Global Impression of Change (PGIC) as the anchor.
- Change From Baseline in the Insomnia Severity Index at Week 4 and Week 12 [ Time Frame: Baseline, Weeks 4 and 12 ]The Insomnia Severity Index was a self-rated, 7-item validated sleep scale that measured clinical insomnia severity. The total score ranged from 0-28 where higher values indicated increased severity of insomnia.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Additional screening criteria check may apply for qualification:
- Provide written informed consent to participate in this study
- Spontaneous amenorrhea for ≥12 months; or spontaneous amenorrhea for at least 6 months and with follicle stimulating hormone (FSH) levels >40 mIU/mL; or documented bilateral salpingo oophorectomy ≥6 weeks, with or without hysterectomy
- 7 or more moderate to severe VMS per day, or 50 or more moderate to severe VMS per week
- Have a consistent bedtime on at least 5 nights per week
- Mean VMS frequency during the Placebo Run in period does not drop by more than 50% from the mean level reported for 2 weeks during the Screening period
- VMS diary compliance >50%
- In the Investigator's opinion, subject is able to understand the nature of the study and any risk involved in participation, and is willing to cooperate and comply with the protocol restrictions and requirements
Exclusion Criteria:
Additional screening criteria check may apply for qualification:
- History of any cancer within 5 years except for basal cell carcinoma
- History of undiagnosed abnormal vaginal bleeding
- History of Hepatitis B, Hepatitis C or HIV
- History of psychiatric illness, excessive alcohol intake or use of recreational drugs who are unsuitable for study enrollment and compliance
- Presence or history of severe adverse reaction or allergy to any drug
- Peripheral vascular disease or disorders with associated vasculopathies
- Clinically significant conditions which could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator
- Endometrial thickness of >=5 mm as measured by transvaginal ultrasound
- Abnormal result from baseline endometrial biopsy (i.e., endometrial hyperplasia or endometrial cancer)
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin ≥2.0 × upper limit of normal (ULN) above the reference range
- Subjects of childbearing potential

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03291067

Study Director: | Head of Clinical Development, | Mitsubishi Tanabe Pharma Development America, Inc. |
Documents provided by Mitsubishi Tanabe Pharma Development America, Inc.:
Responsible Party: | Mitsubishi Tanabe Pharma Development America, Inc. |
ClinicalTrials.gov Identifier: | NCT03291067 |
Other Study ID Numbers: |
MT-8554-A01 |
First Posted: | September 25, 2017 Key Record Dates |
Results First Posted: | January 4, 2022 |
Last Update Posted: | January 4, 2022 |
Last Verified: | December 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Hot Flashes |